The rationale behind the investigation rests on the biology of high-risk human papillomavirus. The viral genes E6 and E7 are the principal oncogenic drivers of HPV-associated cervical transformation: E6 promotes degradation of the p53 tumor suppressor, while E7 disrupts the retinoblastoma protein pathway, together propelling uncontrolled epithelial proliferation. Because these oncogenes are transcribed only when the virus is actively expressing its transforming program, measuring their messenger RNA rather than viral DNA has been proposed as a way to distinguish clinically meaningful, transcriptionally active infections from merely present viral genomes. In theory, a patient whose cervical tissue continues to produce E6/E7 transcripts after excision of a high-grade lesion should carry a higher risk that abnormal epithelium persists or recurs. That theoretical advantage is precisely what the Chinese research team set out to test in a longitudinal clinical setting.

The study enrolled women who underwent LEEP for high-grade cervical lesions and followed them according to a structured surveillance protocol. The first follow-up visit occurred four to six months after the procedure, and monitoring continued for a total of 24 months. During this window, any abnormal finding prompted referral for colposcopy or cervical biopsy, ensuring that recurrence was confirmed through direct visual and histological assessment rather than inferred from laboratory values alone. Both preoperative and postoperative E6/E7 mRNA status were recorded, allowing the investigators to evaluate the marker’s predictive value at two clinically distinct decision points: before surgery, when it might help triage patients for closer surveillance, and after surgery, when it might signal residual disease.

The headline result was strikingly reassuring for patients but sobering for the biomarker. Of the 91 women followed, only three, or 3.30 percent, experienced recurrence within the 24-month observation period. More importantly for the study’s central question, recurrence rates were statistically indistinguishable between women whose preoperative E6/E7 mRNA test was positive and those whose test was negative: 3.23 percent versus 3.45 percent, with a p-value of 0.956 indicating essentially no association. The postoperative comparison told the same story. Among women whose postoperative mRNA result was negative, 5.26 percent recurred, while none of the women with positive postoperative results did, a difference that failed to reach statistical significance with a p-value of 0.814. In both directions, the molecular signal simply did not track with clinical outcome.

One finding did achieve clear statistical significance, and it illustrates how a biologically meaningful change can still fail as a predictive tool. After LEEP, 66.7 percent of patients shifted from E6/E7 mRNA positive to negative status, a transition the authors reported with a p-value below 0.001. This confirms that surgical removal of the lesion substantially reduces the burden of transcriptionally active HPV oncogene expression, which is exactly what one would expect if the excised tissue was the primary source of E6 and E7 transcripts. Yet this dramatic molecular response to treatment carried no information about which patients would later relapse. The women who remained positive after surgery were no more likely to recur than those who converted to negative, undermining the hope that persistent oncogene expression could serve as a red flag during follow-up.

The diagnostic performance statistics quantify just how far the marker falls short of clinical usefulness. Preoperative E6/E7 mRNA testing achieved a sensitivity of 66.67 percent, meaning it correctly identified two of the three women who eventually recurred, but its specificity was only 31.82 percent, meaning it falsely flagged more than two-thirds of women who never experienced recurrence. A test that alarms on the majority of healthy patients while still missing a third of true recurrences offers little practical guidance. The postoperative picture was even more lopsided in the opposite direction: sensitivity dropped to 0 percent, meaning the test caught none of the recurrences at all, while specificity reached 97.30 percent, meaning a positive result was rarely wrong. A biomarker that almost never fires is, for surveillance purposes, almost never useful.

These numbers expose a fundamental asymmetry in what the two time points can offer. A preoperative test with moderate sensitivity but poor specificity cannot meaningfully stratify patients before treatment, because the noise of false positives overwhelms the signal of true risk. A postoperative test with near-perfect specificity but zero sensitivity functions as a rule-in test at best: if it is positive, something may warrant attention, but a negative result provides almost no reassurance. In a disease where recurrence is already rare, at roughly three percent over two years, a surveillance tool must be exceptionally sensitive to justify its place in the clinical pathway, and E6/E7 mRNA failed that threshold decisively in this cohort.

The authors are careful to frame their conclusions within the limits of the study design. With only three recurrence events, the statistical power to detect modest associations is limited, and confidence intervals around the reported sensitivity and specificity estimates are correspondingly wide. The single-center cohort from one hospital in Nanning may not generalize to populations with different HPV prevalence, screening history, or access to care. The 24-month follow-up window, while consistent with standard post-LEEP surveillance intervals, may miss later recurrences. These caveats do not overturn the central finding, but they do mean the results should be read as strong evidence against a strong effect rather than as proof that E6/E7 mRNA has no predictive value under any circumstances.

What the study does establish is a clear negative result with practical consequences. Clinicians and guidelines bodies have been actively searching for biomarkers that could refine post-LEEP surveillance, allowing low-risk patients to return to routine screening intervals while reserving intensive colposcopic follow-up for those at genuine risk of recurrence. HPV DNA testing and cytology remain the backbone of post-treatment surveillance, and this study suggests that adding E6/E7 mRNA to that toolkit, at least as currently implemented, would not improve the identification of women destined to relapse. The significant postoperative clearance of oncogene expression confirms that the biology is real and that the assay detects something meaningful about viral activity; it simply does not translate into prognostic power for recurrence in this population.

The broader lesson for translational research is that a biologically plausible marker must still clear the empirical bar of discriminating outcomes in real patients before it earns a place in clinical algorithms. E6/E7 mRNA has generated considerable enthusiasm in cervical cancer prevention research because it measures the actual expression of the viral genes that drive malignancy, rather than the mere presence of viral DNA. This study demonstrates that enthusiasm must be tempered by outcome data. Until a biomarker demonstrates sufficient sensitivity for the low-recurrence-risk population that follows LEEP, follow-up protocols will continue to rely on the established combination of cytology, HPV DNA testing, and colposcopic examination, and the search for more effective molecular predictors of recurrence remains open.

Subject of Research: Evaluation of HPV E6/E7 mRNA as a biomarker for predicting recurrence of cervical intraepithelial neoplasia after LEEP

Article Title: Evaluation of HPV E6/E7 mRNA in predicting recurrence after Leep in cervical intraepithelial neoplasia: A study of negative findings

Article References: Huang, Y., Huang, J., Jiang, H., Wei, Y., Lin, Z., & Xie, B. (2026). Evaluation of HPV E6/E7 mRNA in predicting recurrence after Leep in cervical intraepithelial neoplasia: A study of negative findings. PLOS One, 21(10), e0360914. https://doi.org/10.1371/journal.pone.0360914

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360914

Keywords: HPV E6/E7 mRNA, cervical intraepithelial neoplasia, LEEP, recurrence, biomarker, cervical cancer screening, colposcopy, follow-up, sensitivity, specificity, PLOS One, Evaluation